NASDAQ:GEMP Gemphire Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.47 -0.36 (-6.17 %) (As of 09/23/2020 12:00 AM ET) Add Compare Share Today's Range$5.39Now: $5.47▼$6.0150-Day Range$0.30MA: $6.04▼$7.0252-Week Range$0.24Now: $5.47▼$1.49Volume21,858 shsAverage Volume127,174 shsMarket Capitalization$81.35 millionP/E RatioN/ADividend YieldN/ABeta2.82 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Gemphire Therapeutics. Previous Next 2.7 Community Rank Outperform VotesGemphire Therapeutics has received 288 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGemphire Therapeutics has received 249 “underperform” votes. (Add your “underperform” vote.)Community SentimentGemphire Therapeutics has received 53.63% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote “Outperform” if you believe GEMP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GEMP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGemphire Therapeutics does not currently pay a dividend.Dividend GrowthGemphire Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gemphire Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 22.70% of the stock of Gemphire Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.53% of the stock of Gemphire Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioGemphire Therapeutics has a P/B Ratio of 10.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GEMP Previous Symbol CUSIPN/A CIK1638287 Webwww.gemphire.com Phone734-245-1700Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book10.13Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-23,640,000.00 Net MarginsN/A Return on Equity-419.70% Return on Assets-173.05%Miscellaneous Employees9 Outstanding Shares14,872,000Market Cap$81.35 million Next Earnings DateN/A OptionableOptionable $5.47 -0.36 (-6.17 %) (As of 09/23/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GEMP News and Ratings via Email Sign-up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions How has Gemphire Therapeutics' stock price been impacted by COVID-19? Gemphire Therapeutics' stock was trading at $14.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GEMP stock has decreased by 62.3% and is now trading at $5.47. View which stocks have been most impacted by COVID-19. How were Gemphire Therapeutics' earnings last quarter? Gemphire Therapeutics Inc (NASDAQ:GEMP) issued its quarterly earnings results on Friday, March, 15th. The company reported ($0.26) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.15. View Gemphire Therapeutics' earnings history. Who are some of Gemphire Therapeutics' key competitors? Some companies that are related to Gemphire Therapeutics include Magenta Therapeutics (MGTA), Catalyst Pharmaceuticals (CPRX), IMV (IMV), Aeglea Bio Therapeutics (AGLE), AMAG Pharmaceuticals (AMAG), CytomX Therapeutics (CTMX), Concert Pharmaceuticals (CNCE), Xeris Pharmaceuticals (XERS), Urovant Sciences (UROV), Aquestive Therapeutics (AQST), MediciNova (MNOV), Aldeyra Therapeutics (ALDX), Chiasma (CHMA), Paratek Pharmaceuticals (PRTK) and Selecta Biosciences (SELB). View all competitors. What other stocks do shareholders of Gemphire Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Micron Technology (MU), Pixelworks (PXLW), SCYNEXIS (SCYX), Protalix Biotherapeutics (PLX), Alexion Pharmaceuticals (ALXN), Anavex Life Sciences (AVXL), Clearside Biomedical (CLSD), Intel (INTC) and Iovance Biotherapeutics (IOVA). Who are Gemphire Therapeutics' key executives? Gemphire Therapeutics' management team includes the following people: Dr. Charles L. Bisgaier, Co-Founder, Chairman & Chief Scientific Officer (Age 65)Dr. Steven R. Gullans, CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer (Age 66)Mr. Seth Reno, Chief Commercial Officer (Age 52)Mr. Jeffrey S. Mathiesen C.P.A., CPA, Consultant (Age 58)Ms. Amy Zaremba Rabourn, Director of Fin. When did Gemphire Therapeutics IPO? (GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers. What is Gemphire Therapeutics' stock symbol? Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP." How do I buy shares of Gemphire Therapeutics? Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Gemphire Therapeutics' stock price today? One share of GEMP stock can currently be purchased for approximately $5.47. How big of a company is Gemphire Therapeutics? Gemphire Therapeutics has a market capitalization of $81.35 million. Gemphire Therapeutics employs 9 workers across the globe. What is Gemphire Therapeutics' official website? The official website for Gemphire Therapeutics is www.gemphire.com. How can I contact Gemphire Therapeutics? Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
